![]() |
|
|
|
Registered
|
I hate biotech
check chart of NBIX to see why.
__________________
1989 3.2 Carrera coupe; 1988 Westy Vanagon, Zetec; 1986 E28 M30; 1994 W124; 2004 S211 What? Uh . . . “he” and “him”? |
||
![]() |
|
Blockchain Tech Inventor
Join Date: Jan 1999
Location: US fn A!
Posts: 1,546
|
![]()
__________________
A Mean Green Lifted 1972 C10 Long live the king! |
||
![]() |
|
Registered
Join Date: Dec 2005
Location: Long Island, NY
Posts: 232
|
ooooouuuuuuuuuuchhhhhhh.....that's why I stick to mutual funds now. learned my lesson after dumping a butt load into a tech stock on sept 8, 2001.
what happened? did the FDA reject something? hope you didn't take too much of a beating
__________________
1991 944S2 Guards Red |
||
![]() |
|
Registered
|
Yuck, what a drag.
Im still deep in NUVO and ALKS, heres hoping I don't have your luck.
__________________
'75 911S 3.0L '75 914 3.2 Honda J '67 912R-STi '05 Cayenne Turbo '99 LR Disco 2, gone but not forgotten |
||
![]() |
|
Registered
|
FDA rejected the long-acting dose of their insomnia drug. The short-acting dose was approved.
Big shock. Investors thought drug would either be approved outright, or approvable (will approve after resolve some final issues). No one imagined FDA would answer NON-approvable. Clinical data showed efficacy and no safety issues. Company said FDA letter indicated agency did not have enough time to review all data. This is hard to reconcile with a NON-approvable, but also makes no sense for management to misrepresent a letter that will be promptly examined by securities lawyers. So something weird has happened. Under an optimistic scenario, they satisfy FDA concerns and get approval in several months or a year. By then more insomnia drugs are on the market and PFE (who will market the drug) may be less committed to it. Under a pessimistic scenario, the long-acting dose is dead, PFE won't market the drug, and hard to see the company's future. Closed at $54 the day before. After the news was announced, the stock started trading pre-open at $30. Fell as people digested the news, was $25 by the time the market opened. Ended the day at $20. During the day, volume was roughly equal to the entire share count. Remarkable. But not that remarkable for biotech, unfortunately.
__________________
1989 3.2 Carrera coupe; 1988 Westy Vanagon, Zetec; 1986 E28 M30; 1994 W124; 2004 S211 What? Uh . . . “he” and “him”? |
||
![]() |
|